The Journal of antimicrobial chemotherapy · 2003
Susceptibility of Bacillus anthracis to eleven antimicrobial agents including novel fluoroquinolones and a ketolide.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Frean John, Klugman Keith P, Arntzen Lorraine, Bukofzer Stanley
Аннотация
OBJECTIVES: To determine the susceptibility of southern African strains of Bacillus anthracis to new, investigational agents as well as conventional antibiotics.
MATERIALS AND METHODS: The MICs of 26 isolates of B. anthracis from South Africa and Zimbabwe, as well as the Sterne vaccine strain and a type culture strain, were determined by agar dilution.
RESULTS: The most active antimicrobial agents were the novel ketolide ABT 773, new and conventional fluoroquinolones, and doxycycline; macrolides were intermediately active. The lack of activity of extended-spectrum cephalosporins against B. anthracis was confirmed.
CONCLUSIONS: Susceptibility to conventional antibiotics was in keeping with previous studies. Two new fluoroquinolones and a ketolide showed promising in vitro activity that would support their further evaluation in animal models of anthrax.
MATERIALS AND METHODS: The MICs of 26 isolates of B. anthracis from South Africa and Zimbabwe, as well as the Sterne vaccine strain and a type culture strain, were determined by agar dilution.
RESULTS: The most active antimicrobial agents were the novel ketolide ABT 773, new and conventional fluoroquinolones, and doxycycline; macrolides were intermediately active. The lack of activity of extended-spectrum cephalosporins against B. anthracis was confirmed.
CONCLUSIONS: Susceptibility to conventional antibiotics was in keeping with previous studies. Two new fluoroquinolones and a ketolide showed promising in vitro activity that would support their further evaluation in animal models of anthrax.